Show simple item record

dc.contributor.authorBrynjolfsson, Siggeir F
dc.contributor.authorBjarnarson, Stefania P
dc.contributor.authorMori, Elena
dc.contributor.authorDel Giudice, Giuseppe
dc.contributor.authorJonsdottir, Ingileif
dc.date.accessioned2012-05-14T10:06:39Z
dc.date.available2012-05-14T10:06:39Z
dc.date.issued2011-11
dc.date.submitted2012-05-14
dc.identifier.citationClin. Vaccine Immunol. 2011, 18 (11):1936-42en_GB
dc.identifier.issn1556-679X
dc.identifier.pmid21900528
dc.identifier.doi10.1128/CVI.05247-11
dc.identifier.urihttp://hdl.handle.net/2336/223480
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractMycobacterium bovis BCG is administered to human neonates in many countries worldwide. The objective of the study was to assess if BCG could act as an adjuvant for polysaccharide-protein conjugate vaccines in newborns and thereby induce protective immunity against encapsulated bacteria in early infancy when susceptibility is high. We assessed whether BCG could enhance immune responses to a meningococcal C (MenC) conjugate vaccine, MenC-CRM(197), in mice primed as neonates, broaden the antibody response from a dominant IgG1 toward a mixed IgG1 and IgG2a/IgG2b response, and increase protective efficacy, as measured by serum bactericidal activity (SBA). Two-week-old mice were primed subcutaneously (s.c.) with MenC-CRM(197). BCG was administered concomitantly, a day or a week before MenC-CRM(197). An adjuvant effect of BCG was observed only when it was given concomitantly with MenC-CRM(197), with increased IgG response (P = 0.002) and SBA (8-fold) after a second immunization with MenC-CRM(197) without BCG, indicating increased T-cell help. In neonatal mice (1 week old) primed s.c. with MenC-CRM(197) together with BCG, MenC-polysaccharide (PS)-specific IgG was enhanced compared to MenC-CRM(197) alone (P = 0.0015). Sixteen days after the second immunization with MenC-CRM(197), increased IgG (P < 0.05), IgG1 (P < 0.05), IgG2a (P = 0.06), and IgG2b (P < 0.05) were observed, and only mice primed with MenC-CRM(197) plus BCG showed affinity maturation and detectable SBA (SBA > 128). Thus, vaccination with a meningococcal conjugate vaccine (and possibly with other conjugates) may benefit from concomitant administration of BCG in the neonatal period to accelerate and enhance production of protective antibodies, compared to the current infant administration of conjugate which follows BCG vaccination at birth.
dc.language.isoenen
dc.publisherAmerican Society for Microbiologyen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209029/?tool=pubmeden_GB
dc.rightsArchived with thanks to Clinical and vaccine immunology : CVIen_GB
dc.subject.meshAdjuvants, Immunologicen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshAnimals, Newbornen_GB
dc.subject.meshAntibodies, Bacterialen_GB
dc.subject.meshBCG Vaccineen_GB
dc.subject.meshBlood Bactericidal Activityen_GB
dc.subject.meshImmunization, Secondaryen_GB
dc.subject.meshImmunoglobulin Gen_GB
dc.subject.meshInjections, Subcutaneousen_GB
dc.subject.meshMeningococcal Vaccinesen_GB
dc.subject.meshMiceen_GB
dc.subject.meshVaccinationen_GB
dc.titleConcomitant administration of Mycobacterium bovis BCG with the meningococcal C conjugate vaccine to neonatal mice enhances antibody response and protective efficacy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Immunology, Landspitali The National University Hospital, Reykjavík, Iceland.en_GB
dc.identifier.journalClinical and vaccine immunology : CVIen_GB
html.description.abstractMycobacterium bovis BCG is administered to human neonates in many countries worldwide. The objective of the study was to assess if BCG could act as an adjuvant for polysaccharide-protein conjugate vaccines in newborns and thereby induce protective immunity against encapsulated bacteria in early infancy when susceptibility is high. We assessed whether BCG could enhance immune responses to a meningococcal C (MenC) conjugate vaccine, MenC-CRM(197), in mice primed as neonates, broaden the antibody response from a dominant IgG1 toward a mixed IgG1 and IgG2a/IgG2b response, and increase protective efficacy, as measured by serum bactericidal activity (SBA). Two-week-old mice were primed subcutaneously (s.c.) with MenC-CRM(197). BCG was administered concomitantly, a day or a week before MenC-CRM(197). An adjuvant effect of BCG was observed only when it was given concomitantly with MenC-CRM(197), with increased IgG response (P = 0.002) and SBA (8-fold) after a second immunization with MenC-CRM(197) without BCG, indicating increased T-cell help. In neonatal mice (1 week old) primed s.c. with MenC-CRM(197) together with BCG, MenC-polysaccharide (PS)-specific IgG was enhanced compared to MenC-CRM(197) alone (P = 0.0015). Sixteen days after the second immunization with MenC-CRM(197), increased IgG (P < 0.05), IgG1 (P < 0.05), IgG2a (P = 0.06), and IgG2b (P < 0.05) were observed, and only mice primed with MenC-CRM(197) plus BCG showed affinity maturation and detectable SBA (SBA > 128). Thus, vaccination with a meningococcal conjugate vaccine (and possibly with other conjugates) may benefit from concomitant administration of BCG in the neonatal period to accelerate and enhance production of protective antibodies, compared to the current infant administration of conjugate which follows BCG vaccination at birth.


This item appears in the following Collection(s)

Show simple item record